Literature DB >> 23178976

The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism.

Sylvia Reitter-Pfoertner1, Thomas Waldhoer, Michaela Mayerhofer, Ernst Eigenbauer, Cihan Ay, Christine Mannhalter, Paul Alexander Kyrle, Ingrid Pabinger.   

Abstract

Data on the long-term survival following venous thromboembolism (VTE) are rare, and the influence of thrombophilia has not been evaluated thus far. Our aim was to assess thrombophilia-parameters as predictors for long-term survival of patients with VTE. Overall, 1,905 out-patients (99 with antithrombin-, protein C or protein S deficiency, 517 with factor V Leiden, 381 with elevated factor VIII and 160 with elevated homocysteine levels, of these 202 had a combination and 961 had none of these risk factors) were included in the study between September 1, 1994 and December 31, 2007. Retrospective survival analysis showed that a total of 78 patients (4.1%) had died during the analysis period, among those four of definite or possible pulmonary embolism and four of bleeding. In multivariable analysis including age and sex an association with increased mortality was found for hyperhomocysteinemia (hazard ratio 2.0 [1.1.-3.5]) whereas this was not the case for all other investigated parameters. We conclude that the classical hereditary thrombophilia risk factors did not have an impact on the long-term survival of patients with a history of VTE. Thus our study supports the current concept that thrombophilia should not be a determinant for decision on long term anticoagulation. However, hyperhomocysteinaemia, known as a risk factor for recurrent VTE and arterial disease, might impact survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178976     DOI: 10.1160/TH12-05-0361

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

Review 1.  Role of thrombophilia testing: con.

Authors:  Scott M Stevens
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

2.  [Choosing wisely recommendations in angiology].

Authors:  O J Müller; R Sternitzky
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

3.  Recurrent venous thromboembolism in a patient with heterozygous factor v leiden mutation.

Authors:  C Whitney White; Angela R Thomason; Valerie Prince
Journal:  Hosp Pharm       Date:  2014-09

Review 4.  Guidance for the evaluation and treatment of hereditary and acquired thrombophilia.

Authors:  Scott M Stevens; Scott C Woller; Kenneth A Bauer; Raj Kasthuri; Mary Cushman; Michael Streiff; Wendy Lim; James D Douketis
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

5.  ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism.

Authors:  Carlo D'Agostino; Pietro Zonzin; Iolanda Enea; Michele Massimo Gulizia; Walter Ageno; Piergiuseppe Agostoni; Michele Azzarito; Cecilia Becattini; Amedeo Bongarzoni; Francesca Bux; Franco Casazza; Nicoletta Corrieri; Michele D'Alto; Nicola D'Amato; Andrea Maria D'Armini; Maria Grazia De Natale; Giovanni Di Minno; Giuseppe Favretto; Lucia Filippi; Valentina Grazioli; Gualtiero Palareti; Raffaele Pesavento; Loris Roncon; Laura Scelsi; Antonella Tufano
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

6.  Thrombophilia Impact on Treatment Decisions, Subsequent Venous or Arterial Thrombosis and Pregnancy-Related Morbidity: A Retrospective Single-Center Cohort Study.

Authors:  Kristina Vrotniakaite-Bajerciene; Tobias Tritschler; Katarzyna Aleksandra Jalowiec; Helen Broughton; Justine Brodard; Naomi Azur Porret; Alan Haynes; Alicia Rovo; Johanna Anna Kremer Hovinga; Drahomir Aujesky; Anne Angelillo-Scherrer
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.